<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04687930</url>
  </required_header>
  <id_info>
    <org_study_id>8122020</org_study_id>
    <nct_id>NCT04687930</nct_id>
  </id_info>
  <brief_title>Genicular Nerve Block in Juvenile Idiopathic Arthritis</brief_title>
  <official_title>Genicular Nerve Block in Juvenile Idiopathic Arthritis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sohag University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sohag University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      N=104 juvenile idiopathic arthritis patients diagnosed after ILAR criteria with unilateral&#xD;
      persistent knee arthritis. They will be randomly assigned into two groups; group 1 will&#xD;
      receive genicular nerve block, group 2 intra-articular triamcinolone. Both groups will be&#xD;
      examined by SOLAR ultrasound scoring system, Visual analogue scale and Lysholm score at 0, 2&#xD;
      and 12 weeks. A semi-quantitative score will be used to assess tenderness and swelling at the&#xD;
      same intervals.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 1, 2020</start_date>
  <completion_date type="Actual">February 15, 2021</completion_date>
  <primary_completion_date type="Actual">February 15, 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in SOLAR score over time</measure>
    <time_frame>Baseline, 2 weeks and 12 weeks</time_frame>
    <description>score to assess ultrasound parameters of the knee including power doppler and grey scale measures</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in visual analogue scale over time</measure>
    <time_frame>Baseline, 2 weeks and 12 weeks</time_frame>
    <description>a graded score for pain evaluation filled by the patient graded from 0 to 10</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Lysholm score over time</measure>
    <time_frame>Baseline, 2 weeks and 12 weeks</time_frame>
    <description>a score to assess knee function. This questionnaire has 8 domains. A score between 95 and 100 means excellent functional performance, good 84-94, fair 65-83 and poor &lt;64</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in semiquantitative score for swelling and tenderness over time</measure>
    <time_frame>Baseline, 2 weeks and 12 weeks</time_frame>
    <description>A score graded from 0 to 3; score 0 means no swelling nor tenderness and 3 means maximum swelling and tenderness</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">104</enrollment>
  <condition>Juvenile Idiopathic Arthritis</condition>
  <condition>Persistent Knee Arthritis</condition>
  <condition>no Intra-articular Injection in the Last 3 Months</condition>
  <condition>no Other Cause for Chronic Kneearthritis</condition>
  <arm_group>
    <arm_group_label>Active genicular nerve block group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>group 1 will receive genicular nerve block. The injection and US examination will be done by two experienced sonographers. They were blinded to clinical data. Patients will also be blinded for the injected substance. Each point will be injected with 2 ml of Lidocaine hydrochloride 2 % (Xylocaine, Astrazeneca). The injection will be done using the 3 point technique (superior medial, superior lateral, and inferior medial genicular nerves).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>intra-articular steroid injection group</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>while group 2 received intra-articular triamcinolone under ultrasound guidance and through injecting the supra-patellar bursa.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>genicular nerve block</intervention_name>
    <description>nerve block of the genicular nerve at 3 points around the inflamed knee using ultrasound.</description>
    <arm_group_label>Active genicular nerve block group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>intra-articular steroid injection</intervention_name>
    <description>Triamcinilone injection into the knee joint under ultrasound guidance.</description>
    <arm_group_label>intra-articular steroid injection group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  juvenile idiopathic arthritis with persistent knee arthritis&#xD;
&#xD;
          -  age below 16&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  severe knee osteoarthritis&#xD;
&#xD;
          -  peripheral neuropathy,&#xD;
&#xD;
          -  psoriatic arthritis,&#xD;
&#xD;
          -  those under anticoagulant therapy, skin infection,&#xD;
&#xD;
          -  prior knee injection in the last 3 months3&#xD;
&#xD;
          -  those who have an allergy to Bupivacaine&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>16 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Sohag university</name>
      <address>
        <city>Sohag</city>
        <zip>82749</zip>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>December 19, 2020</study_first_submitted>
  <study_first_submitted_qc>December 23, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 29, 2020</study_first_posted>
  <last_update_submitted>July 18, 2021</last_update_submitted>
  <last_update_submitted_qc>July 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sohag University</investigator_affiliation>
    <investigator_full_name>Ahmed Mahrous</investigator_full_name>
    <investigator_title>Associate professor</investigator_title>
  </responsible_party>
  <keyword>Juvenile rheumatoid arthritis</keyword>
  <keyword>knee joint</keyword>
  <keyword>Nerve block</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Juvenile</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

